Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Invesco Dynamic Large Cap Growth ETF (PWB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWB

Quidel's (QDEL) Antigen Tests Successful in Omicron Detection

by Zacks Equity Research

The success of Quidel's (QDEL) antigen tests against Omicron is expected to lead to better access to affordable COVID-19 testing.

Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Thermo Fisher Scientific (TMO) closed at $662.73, marking a +1.12% move from the previous day.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

Envista (NVST) Gets FDA 510 (k) Approval for N1 Implant System

by Zacks Equity Research

Envista (NVST) noted that the Nobel Biocare N1 system represents a significant step further in patient-centric dental implant solutions.

PacBio's (PACB) New Surveillance Kit Successful Against Omicron

by Zacks Equity Research

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

Abbott (ABT) Diagnostic and Nutrition Arms Grow Worldwide

by Zacks Equity Research

Abbott (ABT) registers strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) broad array of services.

IDEXX's (IDXX) Organic Growth Robust, LPD Revenues Decline

by Zacks Equity Research

IDEXX's (IDXX) global Reference Lab businesses continue to be robust driven by high same-store volume growth with strong gains across testing categories.

Alcon (ALC) Vision Care Sales Grow Despite Supply Disruption

by Zacks Equity Research

Alcon's (ALC) new contact lenses are gaining market share and the Systane brand family has been posting strong double-digit growth in all regions.

Abbott (ABT) Scales to a 52-Week High: What's Driving It?

by Zacks Equity Research

Strength in Diabetes Care and Diagnostics businesses is driving Abbott's (ABT) top line.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

OPKO's (OPK) RAYALDEE Favored by Trial Data for COVID Patients

by Zacks Equity Research

Latest trial results indicate that using OPKO's (OPK) RAYALDEE may improve vitamin D status for faster relief from respiratory symptoms for COVID-19 patients.

LabCorp (LH) to Expand Oncology Portfolio With Latest Buyout

by Zacks Equity Research

LabCorp's (LH) acquisition of PGDx will position the company at the forefront of driving better patient outcomes in oncology.

Here's Why You Should Hold on to Integra (IART) Stock for Now

by Zacks Equity Research

Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.

Urmimala Biswas headshot

Forget Zimmer Biomet (ZBH), Buy These 3 Medical Devices Stocks

by Urmimala Biswas

With orthopedic stocks like Zimmer Biomet (ZBH) are grappling with several issues, it is wise to invest in medical device stocks like TMO, NEOG and CERN instead for 2022.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

BD (BDX) Partners With Retailers for At-Home COVID-19 Test

by Zacks Equity Research

BD (BDX) collaborates with retail partners and distributors to make the BD Veritor At-Home COVID-19 Test widely accessible.

Quidel (QDEL) Inks Buyout Deal to Solidify Its Diagnostics Arm

by Zacks Equity Research

Quidel's (QDEL) latest buyout is expected to expand its point-of-care diagnostics portfolio as well as geographic footprint.

Thermo Fisher (TMO) Releases New Update for Omicron Detection

by Zacks Equity Research

Thermo Fisher's (TMO) TaqMan SARS-CoV-2 Mutation Panel currently offers direct identification of the novel variant of concern.

Hologic (HOLX) to Meet High Testing Demand With Panther Trax

by Zacks Equity Research

Hologic's (HOLX) Panther Trax scalable solutions will meet the needs of today's laboratories, enabling them to expand operational capacity and testing volumes.

Thermo Fisher Scientific (TMO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Thermo Fisher Scientific (TMO) closed the most recent trading day at $650.70, moving -0.15% from the previous trading session.